



Universiteit
Leiden
The Netherlands

Healthy elderly in clinical trials: how to define preclinical Alzheimer's Disease for clinical trial participation

Prins, S.

Citation

Prins, S. (2023, April 5). *Healthy elderly in clinical trials: how to define preclinical Alzheimer's Disease for clinical trial participation*.

Retrieved from <https://hdl.handle.net/1887/3590274>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3590274>

Note: To cite this publication please use the final published version (if applicable).

HEALTHY ELDERLY IN CLINICAL TRIALS

HOW TO DEFINE PRECLINICAL ALZHEIMER'S DISEASE
FOR CLINICAL TRIAL PARTICIPATION

VOOR MAMA

HEALTHY ELDERLY IN CLINICAL TRIALS

HOW TO DEFINE PRECLINICAL ALZHEIMER'S DISEASE FOR CLINICAL TRIAL PARTICIPATION

PROEFSCHRIFT

Ter verkrijging van de graad van Doctor
aan de Universiteit Leiden op gezag van
Rector magnificus prof.dr.ir. H. Bijl
volgens besluit van het College van Promoties
te verdedigen op woensdag 5 april 2023
klokke 10:00 uur

DOOR

Samantha Prins
Geboren te Hillegom in 1987

Promotores:

Prof.dr. G.J. Groeneveld

Prof.dr. J.M.A. van Gerven

Co-promotor:

dr. Laura Borghans

Leden promotiecommissie:

Prof.dr. Huub Middelkoop

Prof.dr. Charlotte Teunissen (Amsterdam Universitair Medisch Centrum)

Prof.dr. Gerard Jan Blauw

dr Niels Prins (Brain Research Center)

Photography

Samantha Prins

Design

Caroline de Lint, Den Haag (caro@delint.nl)

The publication of this thesis was financially supported by the foundation
Centre for Human Drug Research (CHDR) in Leiden, the Netherlands

	CHAPTER I
7	Introduction
	CHAPTER II
29	Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery
	CHAPTER III
49	Utility of animal models to understand human Alzheimer's disease, using the mastermind research approach to avoid unnecessary further sacrifices of animals
	CHAPTER IV
85	A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation
	CHAPTER V
105	The usefulness of plasma amyloid as a prescreener for the earliest Alzheimer pathological changes depends on the study population
	CHAPTER VI
109	Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease
	CHAPTER VII
125	Neurocognitive functions are not impaired in subjects with preclinical AD based on CSF A β and higher levels of CSF P-TAU217
	CHAPTER VIII
143	Summary and Discussion
157	Nederlandse samenvatting
167	Curriculum Vitae
169	List of publications